Currently, individuals with government healthcare coverage, such as Medicare, Medicaid, or TRICARE, are not eligible for the Bioverse Weight Loss Program, as these plans typically do not cover GLP-1 medications
7 The challenge for clinicians is to detect and intervene in affected individuals
Coverage denials remain common
A recent double-blind RCT of semaglutide versus placebo, published in the New England Journal of Medicine last month, showed meaningful gains in pain and function
Because the medication improves how the body handles insulin and processes sugar, many patients see positive changes in their blood glucose readings and a reduction in cardiovascular risk factors
PlexusDx's personalized approach helps you achieve sustained weight loss improvements that translate to liver health benefits